<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011487</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC B2021-167-01</org_study_id>
    <nct_id>NCT05011487</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC</brief_title>
  <acronym>NOCE01</acronym>
  <official_title>Neoadjuvant Osimertinib Plus Chemotherapy for EGFR-mutant Stage III N2 Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination&#xD;
      with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2)&#xD;
      non-squamous non-small cell lung cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>osimertinib plus chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete lymph node clearance rate</measure>
    <time_frame>From date of enrollment to an average of 12 weeks after the first dose</time_frame>
    <description>the ratio of ypN0 percentage after resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Pathological Response (MPR)</measure>
    <time_frame>From date of enrollment to an average of 12 weeks after the first dose</time_frame>
    <description>Defined as ≤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR)</measure>
    <time_frame>From date of enrollment to an average of 12 weeks after the first dose</time_frame>
    <description>Defined as absence of any residual cancer cells in the dissected tumour samples, including the main tumour and lymph nodes, assessed post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstaging</measure>
    <time_frame>From date of enrollment to an average of 12 weeks after the first dose</time_frame>
    <description>Measured using pathologic mediastinal lymph node evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>From date of enrollment up to approximately 42 months after date of resection</time_frame>
    <description>DFS is defined as the time from the date of surgery until the first date of disease recurrence (local or distant) or date of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>osimertinib plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib (80mg/qd) po. for 60 days with two cycles of Pemetrexed (500 mg/m2) to be administered with cisplatin (75mg/m2) on Day 1 of every 3-week cycle for 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>80mg/qd oral for 60 days</description>
    <arm_group_label>osimertinib plus chemotherapy</arm_group_label>
    <other_name>AZD9291</other_name>
    <other_name>TAGRISSO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.</description>
    <arm_group_label>osimertinib plus chemotherapy</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles</description>
    <arm_group_label>osimertinib plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented N2 positive non-squamous NSCLC with&#xD;
             resectable (Stage IIIA or T3-4N2 IIIB) disease (according to Version 8 of the IASLC&#xD;
             Cancer Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016]).&#xD;
&#xD;
          -  Complete surgical resection of the primary NSCLC must be deemed achievable, as&#xD;
             assessed by a MDT evaluation (which should include a thoracic surgeon, specialized in&#xD;
             oncologic procedures).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at enrolment, with no&#xD;
             deterioration over the previous 2 weeks prior to baseline or day of first dosing&#xD;
&#xD;
          -  A tumour which harbours one of the 2 common EGFR mutations known to be associated with&#xD;
             EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR&#xD;
             mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required&#xD;
             steroid treatment, or any evidence of clinically active ILD.&#xD;
&#xD;
          -  History of another primary malignancy, except for the following: Malignancy treated&#xD;
             with curative intent and with no known active disease ≥2 years before the first dose&#xD;
             of investigational product (IP) and of low potential risk for recurrence; Adequately&#xD;
             treated non-melanoma skin cancer or lentigo malignancy without evidence of disease;&#xD;
             Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          -  Patients who have pre-operative radiotherapy treatment as part of their care plan&#xD;
&#xD;
          -  Mixed small cell and NSCLC histology&#xD;
&#xD;
          -  T4 tumours infiltrating the aorta, the oesophagus and/or the heart; and/or any bulky&#xD;
             N2 disease deemed unresectable&#xD;
&#xD;
          -  Patients who are candidates to undergo only segmentectomies or wedge resections&#xD;
&#xD;
          -  Prior treatment with any systemic anti-cancer therapy for NSCLC including&#xD;
             chemotherapy, biologic therapy, immunotherapy, or any investigational drug&#xD;
&#xD;
          -  Prior treatment with EGFR-TKI therapy&#xD;
&#xD;
          -  Current use of (or unable to stop use prior to receiving the first dose of study&#xD;
             treatment) medications or herbal supplements known to be strong inducers of cytochrome&#xD;
             P450 (CYP) 3A4 (at least 3 weeks prior)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Yang, Ph.D.,M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Yang, Ph.D.,M.D.</last_name>
    <phone>13560405144</phone>
    <phone_ext>13560405144</phone_ext>
    <email>yanghong@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyang Chen, Ph.D.,M.D.</last_name>
    <phone>008618826238208</phone>
    <email>chenjy1@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Yang, Ph.D.,M.D.</last_name>
      <phone>008613560405144</phone>
      <email>yanghong@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yang Hong</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>EGFR-TKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

